Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emivirine Combination Therapy in HIV-1
NCT00002418Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Emivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Bristol Myers Squibb. Primary endpoints: Plasma HIV-1 RNA levels at 24 weeks, Lymphocyte subsets (CD4 count) at 24 weeks and 2 more. Status: terminated.
02
Drugs
Emivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002418.